Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359377/
https://ncbi.nlm.nih.gov/pubmed/32661118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000891
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados